title: Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.
abstract: Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the production of estrogen. The majority of breast cancers are sensitive to the proliferative effects of estrogen. Exemestane is approved for the adjuvant treatment of postmenopausal women with breast cancer after 2 to 3 years of tamoxifen therapy, based on a 32% improvement in disease-free survival compared with 5 years of tamoxifen alone (P < 0.001). Exemestane has also shown clinical benefits as an upfront therapy. The safety profile of exemestane shares some side effects with tamoxifen (hot flashes and arthralgia), but is not associated with an increased risk of endometrial cancer or thromboembolic events. This review will discuss in detail the efficacy and safety of exemestane in early breast cancer.
authors.affiliation: University of Miami, Leonard M. Miller School of Medicine, 1475 NW 12th Avenue, Suite 3310, Miami, Florida, USA.
authors.forename: Muaiad
authors.initials: M
authors.lastname: Kittaneh
authors.forename: Stefan
authors.initials: S
authors.lastname: Glück
references.citation: Curr Oncol. 2010 Feb;17(1):87-90
references.pmid: 20179809
references.citation: Breast Cancer Res Treat. 1994;30(1):31-42
references.pmid: 7949203
references.citation: Ann Oncol. 2010 Mar;21(3):498-505
references.pmid: 19717534
references.citation: J Clin Oncol. 2000 Apr;18(7):1399-411
references.pmid: 10735887
references.citation: Med Care. 2007 May;45(5):431-9
references.pmid: 17446829
references.citation: Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134
references.pmid: 17610808
references.citation: Gynecol Oncol. 2010 Dec;119(3):500-5
references.pmid: 20832103
references.citation: Am J Health Syst Pharm. 2011 Sep 15;68(18):1699-706
references.pmid: 21880884
references.citation: Drug Metab Dispos. 2011 Jan;39(1):98-105
references.pmid: 20876785
references.citation: Expert Opin Pharmacother. 2010 Aug;11(11):1933-42
references.pmid: 20569090
references.citation: J Clin Oncol. 2007 Jul 1;25(19):2664-70
references.pmid: 17563395
references.citation: Lancet. 2007 Feb 17;369(9561):559-70
references.pmid: 17307102
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1899-905
references.pmid: 17035397
references.citation: J Clin Oncol. 2003 Feb 15;21(4):602-6
references.pmid: 12586795
references.citation: Endocr Rev. 2009 Jun;30(4):343-75
references.pmid: 19389994
references.citation: J Clin Oncol. 2010 Mar 10;28(8):1294-300
references.pmid: 20142601
references.citation: Curr Oncol. 2007 Dec;14 Suppl 1:S11-9
references.pmid: 18087604
references.citation: Breast Cancer Res Treat. 2011 Feb;125(3):741-9
references.pmid: 20821047
references.citation: Breast Cancer Res Treat. 2010 Apr;120(3):525-38
references.pmid: 20157776
references.citation: BMC Med Genomics. 2009 Jul 02;2:40
references.pmid: 19573224
references.citation: Lancet. 2005 Aug 6-12;366(9484):455-62
references.pmid: 16084253
references.citation: Breast Care (Basel). 2009;4(6):389-396
references.pmid: 20877674
references.citation: Breast Cancer Res Treat. 2007;105 Suppl 1:7-17
references.pmid: 17912633
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1965-71
references.pmid: 18332472
references.citation: Curr Oncol. 2007 Dec;14 Suppl 1:S20-40
references.pmid: 18087605
references.citation: Clin Oncol (R Coll Radiol). 2004 Oct;16(7):485-91
references.pmid: 15490811
references.citation: J Clin Endocrinol Metab. 1980 Sep;51(3):473-7
references.pmid: 6773974
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4765-71
references.pmid: 17947724
references.citation: Cancer. 2007 Aug 1;110(3):499-508
references.pmid: 17592825
references.citation: J Clin Oncol. 2010 Nov 1;28(31):4674-82
references.pmid: 20876420
references.citation: Endocr Relat Cancer. 2004 Jun;11(2):179-89
references.pmid: 15163297
references.citation: J Clin Oncol. 2005 Aug 1;23(22):4847-9
references.pmid: 15983395
references.citation: Breast Cancer Res. 2009;11(3):R35
references.pmid: 19531217
references.citation: Crit Rev Oncol Hematol. 2010 Feb;73(2):156-66
references.pmid: 19299162
references.citation: J Clin Oncol. 2008 Oct 20;26(30):4883-90
references.pmid: 18794551
references.citation: Oncology (Williston Park). 2010 Oct;24(11 Suppl 4):1-15
references.pmid: 21284351
references.citation: Breast Care (Basel). 2009;4(3):155-161
references.pmid: 21160541
references.citation: Cancer. 2009 May 1;115(9):1813-26
references.pmid: 19235248
references.citation: N Engl J Med. 2003 Nov 6;349(19):1793-802
references.pmid: 14551341
references.citation: Cancer Res. 1992 Nov 1;52(21):5933-9
references.pmid: 1394219
references.citation: Cancer. 2008 Jan 15;112(2):260-7
references.pmid: 18041059
references.citation: N Engl J Med. 2004 Mar 11;350(11):1081-92
references.pmid: 15014181
references.citation: N Engl J Med. 2009 Aug 20;361(8):766-76
references.pmid: 19692688
references.citation: Ann Oncol. 2009 Jan;20(1):49-55
references.pmid: 18678766
references.citation: J Clin Oncol. 2010 Apr 10;28(11):1829-34
references.pmid: 20212256
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5138-47
references.pmid: 16009955
references.citation: Cancer Invest. 2007 Feb;25(1):6-13
references.pmid: 17364551
references.citation: J Clin Oncol. 2004 Aug 15;22(16):3309-15
references.pmid: 15310774
references.citation: Lancet Oncol. 2007 Feb;8(2):119-27
references.pmid: 17267326
references.citation: Breast Cancer Res Treat. 2010 Nov;124(1):153-61
references.pmid: 20730486
references.citation: Lancet Oncol. 2008 Jan;9(1):45-53
references.pmid: 18083636
references.citation: Breast Cancer Res Treat. 2006 Sep;99(2):215-20
references.pmid: 16541307
references.citation: Endocr Relat Cancer. 2010 Apr 21;17(2):415-30
references.pmid: 20228125
references.citation: Cancer. 2001 Nov 1;92(9):2247-58
references.pmid: 11745278
references.citation: J Clin Oncol. 2007 Jun 20;25(18):2516-21
references.pmid: 17577028
references.citation: Cancer Res. 1982 Aug;42(8 Suppl):3430s-3433s
references.pmid: 7044525
references.citation: Breast Cancer Res Treat. 2007 May;102(3):289-99
references.pmid: 17033927
references.citation: Cancer Res. 1982 Aug;42(8 Suppl):3434s-3436s
references.pmid: 7044526
references.citation: J Clin Oncol. 2001 May 15;19(10):2596-606
references.pmid: 11352951
references.citation: N Engl J Med. 2011 Jun 23;364(25):2381-91
references.pmid: 21639806
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4129-34
references.pmid: 20713855
references.citation: N Engl J Med. 2005 Dec 29;353(26):2747-57
references.pmid: 16382061
references.citation: Cancer. 2006 May 1;106(9):1875-82
references.pmid: 16572409
references.citation: J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71
references.pmid: 16145047
references.citation: Clin Cancer Res. 1997 Jul;3(7):1101-8
references.pmid: 9815789
references.citation: Ann Oncol. 2011 Aug;22(8):1777-82
references.pmid: 21285133
references.citation: Mol Endocrinol. 2007 Feb;21(2):401-14
references.pmid: 17095574
references.citation: Cancer. 1994 Jan 15;73(2):354-61
references.pmid: 8293400
references.citation: Value Health. 2007 Sep-Oct;10(5):367-76
references.pmid: 17888101
references.citation: Lancet. 2005 Jan 1-7;365(9453):60-2
references.pmid: 15639680
references.citation: Anticancer Drugs. 1998 Sep;9(8):675-83
references.pmid: 9823425
references.citation: Breast Cancer Res. 2005;7(3):119-30
references.pmid: 15987442
references.citation: Ann Oncol. 2008 Aug;19(8):1407-1416
references.pmid: 18448451
references.citation: Clin Cancer Res. 2005 Jul 1;11(13):4835-42
references.pmid: 16000581
references.citation: Cancer. 2007 Mar 1;109(5):832-9
references.pmid: 17243168
references.citation: J Clin Oncol. 2008 Dec 1;26(34):5569-75
references.pmid: 18981464
references.citation: Eur J Cancer. 2000 May;36(8):976-82
references.pmid: 10885600
references.citation: Ann Oncol. 2009 Aug;20(8):1319-29
references.pmid: 19535820
references.citation: J Mol Endocrinol. 2000 Aug;25(1):1-16
references.pmid: 10915214
references.citation: Expert Opin Pharmacother. 2009 Jun;10(9):1435-47
references.pmid: 19445563
references.citation: Cancer Res. 1982 Aug;42(8 Suppl):3451s-3453s
references.pmid: 6177405
references.citation: J Clin Oncol. 2008 Feb 1;26(4):556-62
references.pmid: 18180462
references.citation: J Clin Oncol. 2006 Feb 20;24(6):910-7
references.pmid: 16484701
references.citation: Breast Cancer Res Treat. 2010 Feb;120(1):127-34
references.pmid: 20035381
references.citation: Pharmacogenet Genomics. 2010 Oct;20(10):575-85
references.pmid: 20697310
references.citation: Cancer Treat Rev. 2008 May;34(3):275-82
references.pmid: 18082328
references.citation: Lancet. 2011 Jan 22;377(9762):321-31
references.pmid: 21247627
references.citation: Ann Oncol. 2011 Mar;22(3):503-514
references.pmid: 20616198
references.citation: J Clin Oncol. 2003 Nov 1;21(21):4042-57
references.pmid: 12963702
references.citation: J Cancer Res Clin Oncol. 2011 Jun;137(6):1015-25
references.pmid: 21170551